Molecule performance is governed by a complex interplay of factors
Complex antibodies, like multispecifics, are hard to engineer because the relationship between design and function is often non-intuitive. As a consequence, conventional methods are liable to deliver sub-optimal molecules which either fail in the clinic or result in poor patient outcomes.
Introducing the EVA™ platform
We’ve developed EVA™ — a highly automated discovery engine that enables the rapid identification and co-optimisation of complex therapeutic antibodies across multiple key properties.
Complete on/off killing selectivity for therapeutic antibodies
Our platform is both modality and format-agnostic but for our internal pipeline, we’re focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. Our novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.
Our Investors
